US Patent

US7687662 — Proteasome inhibitors

Composition of Matter · Assigned to Millennium Pharmaceuticals Inc · Expires 2027-08-06 · 1y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects novel compounds that inhibit proteasomes and their pharmaceutical compositions for treating various diseases.

USPTO Abstract

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

Drugs covered by this patent

ixazomib-citrate (IXAZOMIB CITRATE)

Patent Metadata

Patent number: US7687662
Jurisdiction: US
Classification: Composition of Matter
Expires: 2027-08-06
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Millennium Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.